Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2009

View Archived Issues

Sanofi-aventis reviews 2008 developments

Novel modulator of muscarinic M1 receptor alleviates cognitive deficit in rodents

Telbivudine shows better efficacy than lamivudine in hepatitis B patients

Chelsea Therapeutics successfully completes phase II trial of CH-1504 in RA

Synergistic effects seen with ZSET-1446 and donepezil in cognitive impairment model

BioPorto Diagnostics launches ELISA kit for measuring APC-PCI biomarker

BEMA buprenorphine to proceed to phase II following favorable results

FDA Advisory Committee recommends approval of Multaq for arrhythmia

OSI submits sNDA for Tarceva as first-line maintenance therapy in NSCLC

Biokine initiates Israeli phase I/IIa clinical study of BKT-140 for myeloma

NeuroSearch claims novel 1,4-diaza-bicyclo[3.3.3]nonyl oxadiazolyl derivatives

Antiepileptic drug shows efficacy in neuropathic pain

Roche prepares and tests novel leukotriene B4 antagonists

Novel PPARalpha ligands discovered by Nagoya Industrial Science Research Institute

CytRx announces efficacy results for iroxanadine in rat model of diabetic peripheral neuropathy

Novel heterocyclic compounds developed by Merck & Co. for the treatment of diabetes

Benefit seen in most symptomatic atopic asthma patients with AMG-317

Small ciliary neurotrophic factor peptides designed to improve cognition

Tapentadol IR found safer than oxycodone IR for the treatment of pain

Novartis patents novel beta-secretase inhibitors

Lux completes enrollment into second phase III LUCIDA clinical trial of Lumitect

Evolva commences phase I clinical trials on EV-077-3201-2TBS

FDA approves once-yearly Reclast to treat steroid-induced osteoporosis

Neoprobe's phase III Lymphoseek study achieves positive results

CHMP adopts negative opinion for aztreonam lysine in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...